Aravive Inc (ARAV) ニュース

Lol suddenly OTCs more reliable than Nasdaq

Aravive, Inc. to Delist from The Nasdaq Stock Market

Hit .1820s again yesterday briefly lol.... this one's a set and forget flipper

Silently creeping up everyday... 5 -10%..

I have a feeling Alternatively that they are letting retail take it up and then when enough of an increase is achieved, they will attempt to dump it back and do this continuously as with every ticker...

This is the only possible explanation for the price action most tickers, slowly grabbing more and more of retail money while the house of cards is collapsing

One day of 100 - 200 million volume sends this flying my brothers and sisters... .11s were a nice bottom for those who got in or out and back in... I stayed in... my eyes are on this for their cancer breakthroughs as my mother died to ovarian cancer and my father to Colan cancer... we all know it was the chemotherapy and hospital conditions inducing pneumonia or morphine inducing heart attacks... But if these guys have some breakthrough Cancer fighting products, they can potentially get bought out as well or sign some more larger deals or add to the revenue stream from China....

Cancer will be huuuuuuge with the pharma, agricultural, Technology and food industries causing cancer....

We all know pharma is making more money then they did him the vaccines off the side effects.

So this is a bottom with good possibilities of a rise in value per share... they were over a dollar only a couple of months back and failed on revenue projections and lack of Full FDA approval. Have faith. Sometimes the rewards come from the place you least expect

Another day building support in .14 and soon .15

Keep watching. We break .20s soon with or without news... News sends this .30+ to .50 or so...

Perhaps there will be a pull back from profit takers, but if we see an FDA APPROVAL.... Good luck chasing

Look at that... support will now build on the .14 - .15 range, hopefully... stylist l similar to avtx when it moved up from .11s to .17s then it tanked again to .10 lol 😆... what to do, what to do...

Zoom out. Support building in .13s... next stop .20+ once more. If the news is solid, .30 .40 open one day

Are we gonna beach .50 cents. I have a feeling, yes we are! Wait for the Earnings next week and #2 Phase 3 Trials underway. Who knows, we might see a garbage quarterly with an FDA approval to pump this up to .50-.60 cents with current share structure as analyst's say.

Good mantra to live by. It's true.

Men in jeans built this country
Men in suits destroyed it.

Due what is best for you
And be peaceful as you do it.

Pretty much. You do the opposite of what they they want and you eventually catch a nice return or for some, a flip... I haven't been one to flip trade. Don't believe in it, but I guess I would be better off if I did...

When they say get vaccinated, it really means, don't... when they say EVs are the future, invest in oil.... when they say someone is a terrorist, they themselves are the terrorists...

You can apply that to every government and institutional narrative lol

Buy’em when they hate ‘em rinse and repeat. Folks will come back in we’re still a strong buy co imo

Just let Pfizer or Eli Lilly buy you out for $5+ a share and be done with this shorting, reverse splitting, share offering scheme B.S

Such an embarrassing turn of events for this company... No communication, no updates, no address to shareholders.

Screw the shareholders is basically the sentiment, while institutions and market makers rape the share price into a Reverse Split followed by a share offering because clearly the have no money to continue operations or maintain trials.

Redeem yourselves Aravive management... Come out with a FULLY FDA APPROVED PRODUCT TO MARKET ADDRESSING THE CONTROVERSIAL FRAUD THAT IS CANCER. Rid the world of this chemotherapy SCAM

One morning they will announce something and you will wake up to .40s .50s or at the least .30s

Mark it

Any day, these bastards can get squeezed PRE or AFTER HOURS... And I'll be right here when that happens. I expect a PR addressing the conference this past weekend

Squeeze the Shorts... make em move into tents! Bring that news, you bankruptcy-bound shittily managed company lol....

They either need a bigger deal than they got in China, or now countries to buy up their cancer treatment remedy....

Or a buy out...

Reverse split and a share offering is another possibility...

We don't want to see a damn a reverse split...

.14s printing again

after Spain down - after 220 milj between 0.16 and 0.26

Lol .13s ...

https://aravive.com/pipeline/

Pipeline

Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation for pancreatic ductal adenocarcinoma. Batiraxcept has been granted Orphan Drug Designation by the European Commission for platinum resistant recurrent ovarian cancer.

Analysis of all safety data to date showed that batiraxcept has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals. A P1B platinum-resistant ovarian cancer trial (N = 53) demonstrated more than a doubling of progression-free survival in a patient subgroup that represents the P3 population.

?

?

Platinum Resistant Ovarian Cancer

Ovarian cancer ranks fifth in cancer deaths among women, and it is estimated by the American Cancer Society that there will be approximately 19,710 new cases of ovarian cancer in the United States and approximately 13,270 ovarian cancer deaths in the United States during 2023. Due to the nonspecific nature of disease symptoms and lack of validated screening tools in the general population, most women present with advanced disease. Although aggressive cytoreductive surgery and platinum- and taxane-based combination chemotherapy can place most patients into remission, disease recurrence manifests in greater than 70% of patients. Ultimately, patients who relapse become platinum-resistant and the identification of effective and tolerable treatment options is considered a high unmet clinical need. We are focused on addressing the high unmet need in this patient population and successfully completed a Phase 1b trial of batiraxcept in patients with platinum resistant ovarian cancer. We have completed enrollment in a registrational Phase 3 trial of batiraxcept in platinum resistant ovarian cancer (NCT04729608).

Clear Cell Renal Cell Carcinoma

Kidney cancer is a leading cause of cancer-related deaths in the United States and is among the 10 most common cancers in both men and women. According to the American Cancer Society, it is estimated that there will be approximately 81,800 new cases of kidney cancer and 14,890 people will die from this disease in the United States during 2023. Clear cell renal cell carcinoma is a cancer of the kidney and accounts for more than 75% of malignant kidney tumors. Metastasis to distant organs including the lung, bone, liver, and brain is the primary cause of death in kidney cancer patients, and only 12% of people with metastatic kidney cancer will survive past 5 years. We have completed enrollment in a Phase 1b/2 clinical trial of batiraxcept in patients with clear cell renal cell carcinoma (NCT04300140).

Pancreatic Adenocarcinoma

Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. The American Cancer Society estimates 64,050 people will be diagnosed with pancreatic cancer and 50,550 people will die of pancreatic cancer in 2023. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030. We have initiated and are recruiting for a Phase 1b/2 clinical trial of batiraxcept in patients with pancreatic adenocarcinoma (NCT04983407).

Lol this is pathetic... it's as if the crash of the entire market is already here

Zoom out and look at the 1 month chart... looks like it'll blow any day... and these guys got some trial candidates going for cancer and finish presenting in Spain today... Any news takes it back to .20s and .30s Pre market or After Hours

Flippers, Group traders and shorting

from 17 oct. to now about 220 milj.shares traded price 0.135 to 0. 285 how can those annalists explain that ?????? now at 0.156

Analyst Firms Making Recommendations

CANTOR FITZGERA

EF HUTTON

H C WAINWRIGHT

WILLIAM BLAIR

Analyst

$0.63

Based on analysts offering 12 month price targets for ARAV in the last 3 months. The average price target is $0.63 with a high estimate of $1 and a low estimate of $0.25.

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAV - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.40.According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.Aravive has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 590.71% upside from current levels. In a report released on October 27, Roth Capital also maintained a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aravive-arav-2?utm_source=advfn.com&utm_medium=

Back in again, love this one, round 3 !

When you have 40+ institutions holding, expect dirty games... They make millions playing dirty

Loading loading loading, to break higher lows and set new highs... .20s soon, 30s not far off and news sets this at $1+ currently presenting until Tuesday in Europe. They will get Approval of their drugs for treatment of cancer... This is a short killer, they go long as well as short playing both sides... But they have the funds to sit this out for months... a don't lose your shares. Add, add, add, if you're in losses, average down

We will see another break through .20 today, whether by 10am or 3pm

ARAV last friday trade 112.074.712 shares between 0.16 to 0.249 more of the complete float and back to 0.163 here is an bis big problem

and yet shorts are not feelin' comfortable, i wonder why.... ANT

Yeah, it's no secret... they pump it up and sell off by end of day. Same repetition on every ticker these days. Volume must sustain week after week and news updates have to come to justify and maintain momentum... a otherwise, you stay sub dollar, reverse split and stay sub dollar once more. Quantitative Easing ended and money supply tightened up... The money supply is now reserved for government agendas like the war in Ukraine and Israel, LGBTQ, Transgender & Gender b.s.... "Climate change," electric vehicles etc lol...

Either you fold or take losses or by some luck you got into the right ticker which rises week over week like HUBC TTOO, TPST GNS in january GTII in february, FNGR in recent weeks etc etc....

If this ticker has a 30-35 mill float and a 70ish mill OS, it might just do it on FDA news... and we're laughing!

ARAV is an stock sell machine

You guys see that George W forming

This one's a lost cause. Dipshits dumping it all afternoon... second time this week. Won't be surprised to see it close .14-.16 tonight

Closing .21 + would be nice going into 8pm

Very possible.

Watch attendees accumulate shares on Monday & Tuesday > October 20 - 24th at ESMO Congress 2023

It's a miracle, I'm in the green aha

So far holding this range, but it can dump and minute or go back up. Let's see. Still news updates are possible since they're presenting at a conference

I think not these way now you have the complete stock from 0.16 and 0249

It's over rover... knifing back to .14 - .16 cents like last time... Flip shit bastards....

Now one must rely on news... Good luck with that, timing of news never lines up with momentum

Now we know the big players who are flipping

Added

Some of the 44 tutes are Baker Bros. Vanguard, Morgan Stanley, Black Rock .....

Investors are forward looking. The company has been growing revenues. Plenty of research costs, but the ongoing FDA phase III trials are catalysts for higher share price.